Remember, this is an Option Agreement to license, not a License Agreement. This agreement gives Amarantus the exclusive option to license the IP for a period of 12 months. If the two parties cannot reach a mutually agreeable licensing arrangement, then I believe the option to license could be rescinded by either party. This is just my reasonable expectation, as I haven't seen the actual contract.

Given the company's licensing of LymPro from the same researcher, this seems like a highly promising combination going forward. I expect both parties understand this and will reach a licensing arrangement that beneficial to both.